Home » Newsletters » BioWorld Science

BioWorld Science

March 17, 2020

View Archived Issues

Repurposing human kinase inhibitors and optimization against drug-resistant S. aureus

BioNTech reports on mRNA vaccine candidate BNT-162 for COVID-19

GOF, LOF mutations take different paths to same result

Promising final phase IIa results presented for IPED-2015 in erectile dysfunction

Results of phase I study of V-934/V-935 hTERT vaccination in patients with selected solid tumors

Octapeptide binds to pANXA2 with calcium-dependent affinity in solid tumors: a new imaging probe

Cerebrospinal fluid cytokines CXCL10/IP-10 and IL-21 can help to diagnose autoimmune encephalitis

Data presented from part 1 of phase II PIONEER study of avapritinib in systemic mastocytosis

Shenzhen Bo Li Jian Medicine presents new IRAK-4 inhibitors

LATS1/LATS2 inhibitors described by Nivien Therapeutics

New enteropeptidase inhibitors identified at SCOHIA PHARMA

Tera Stone discovers xanthine oxidase inhibitors

Menin/MLL interaction inhibitors patented by Sumitomo Dainippon Pharma

XORTX launches new program to treat COVID-19

Galectin-7 as new therapeutic target for the prevention of preeclampsia

GRMS-55 and lisofylline demonstrate promising activity in models of immune-related disorders

First-in-human study evaluates SRK-181 for locally advanced or metastatic solid tumors

COVID-19: Undetected cases are major source of pandemic spread

Relief Therapeutics to study aviptadil for ARDS in patients with COVID-19

NIH doses first patient in phase I study of Moderna's mRNA-1273 against SARS-CoV-2

Novo Nordisk announces decision to pause concizumab trials in hemophilia

InxMed initiates phase Ib trial of IN-10018 for uveal melanoma and NRAS-mutant metastatic melanoma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.